Editas CSO Mark Shearman to step down effective March 31, 2023

Editas Medicine, Inc.

Dr. Shearman departs as CSO and EVP; effective March 31, 2023.
Separation agreement: 12 months base salary, COBRA, and 2022 bonus.
Agreement includes standard non-disparagement and confidentiality clauses.
No successor named; CEO Gilmore O'Neill signed the filing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark S. Shearman

Chief Scientific Officer

EDIT · Editas Medicine, Inc.

Effective: 2023-03-31
Filed: January 9, 2023, 6:59 PM ET

On January 7, 2023, Editas Medicine, Inc. (the “Company”) and Mark S. Shearman, Ph.D., Executive Vice President and Chief Scientific Officer of the Company, agreed that Dr. Shearman will step down as Chief Scientific Officer effective March 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark S. Shearman departed as Chief Scientific Officer at Editas Medicine, Inc..

Action: stepped down
Role: Chief Scientific Officer

Exact text from the filing

On January 7, 2023, Editas Medicine, Inc. (the “Company”) and Mark S. Shearman, Ph.D., Executive Vice President and Chief Scientific Officer of the Company, agreed that Dr. Shearman will step down as Chief Scientific Officer effective March 31, 2023.

View on SEC.gov

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-000130

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.